Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM). Conference Paper uri icon

authors

  • Reardon, David A
  • Kaley, Thomas Joseph
  • Dietrich, Jorg
  • Clarke, Jennifer Leigh
  • Dunn, Gavin
  • Lim, Michael
  • Cloughesy, Timothy Francis
  • Gan, Hui Kong
  • Park, Andrew J
  • Schwarzenberger, Paul
  • Ricciardi, Toni
  • Macri, Mary J
  • Ryan, Aileen
  • Venhaus, Ralph Rudolph

publication date

  • May 20, 2019